Japan Greenlights Commercial iPSC Therapies

Japan has granted conditional, time‑limited approvals for two first‑in‑the‑world medical products made from induced pluripotent stem cells: Amchepry for Parkinson's disease (Sumitomo Pharma) and ReHeart sheets for severe heart failure (Cuorips). Approvals were based on limited patient data and allow manufacture and sale, with rollouts possible within months. — This sets an international precedent for faster commercialization of advanced cell therapies, forcing a debate on regulatory standards, post‑market monitoring, patient access, and commercial incentives in biotech.